Companies ›Consumer Non Cyclicals ›6469.TWO

6469.TWO — TPEx Drug Retailers

6469.Two

$70,10

Open in Charts → Attach watcher ⌖

— —

TWD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

10,5B TWD

P/E

—

EV / Rev

—

Div yield

3,79 %

Op margin

—

ROE

—

Net margin

—

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

6469.TWO operates in the drug retailing industry, selling pharmaceuticals and related health products to consumers.

Business. 6469.TWO operates in the drug retailing industry, selling pharmaceuticals and related health products to consumers.

Classification92 %

SectorConsumer Non-Cyclicals

Business sectorFood & Drug Retailing

IndustryDrug Retailers

ActivityFood & Drug Retailing

Generated · model-assisted

Sell-side consensus

HOLD4 analysts

0 buy3 hold1 sell

Avg 12m price target90,00

Analyst recommendations

4 analysts · consensus Hold

Buy0

Hold3

Sell1

12-month price target

90,00

Consensus of sell-side coverage.

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Hold

4 analysts · indicative

Ownership

—

not yet wired

Profitability

—

not yet wired

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning 6469.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples · THIS SECTOR−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to 6469.TWO. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

6469.TWO operates in the drug retailing industry, selling pharmaceuticals and related health products to consumers.

Classification92 %

SectorConsumer Non-Cyclicals

Business sectorFood & Drug Retailing

IndustryDrug Retailers

ActivityFood & Drug Retailing

AI synthesis

GENERATED

The company has a market capitalization of 10.45 billion TWD, with a current market price of 69.8 TWD per share. Analysts have set a mean price target of 90.00 TWD, indicating a potential upside of 29% from the current price. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents.

Profitability and return metrics are not available in the provided data, making it difficult to compare the company's performance against industry benchmarks. Without access to key financial ratios such as ROIC or EBITDA margins, a detailed assessment of profitability is not possible.

The company's segment and geographic exposure are not disclosed in the available data, limiting the ability to assess revenue concentration or diversification. Analysts have not provided a growth trajectory or revenue outlook for the company, and no historical revenue data is available to infer a trend.

The risk assessment indicates a low dilution potential, with no significant dilution sources identified in the source documents. However, the absence of balance-sheet data and going-concern language raises concerns about the company's financial stability and liquidity.

No recent events, such as filings or transcripts, are available in the provided data to inform the company's current strategic or operational direction.

Key takeaways

The company has a market capitalization of 10.45 billion TWD and a current market price of 69.8 TWD per share.
Analysts have set a mean price target of 90.00 TWD, suggesting a potential upside of 29%.
Liquidity risk could not be assessed due to the absence of balance-sheet data and no going-concern language in the source documents.
Profitability and return metrics are not available, making it difficult to compare the company's performance against industry benchmarks.
The company's segment and geographic exposure are not disclosed, limiting the ability to assess revenue concentration or diversification.
No recent events or filings are available to inform the company's current strategic or operational direction.

Bull / Bear case

analysis pipeline

— missing data

In focus — financials by report

Valuation

Market price

$70,10

Market cap

$10.45B

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

—

Net cashⓘ

—

Current ratioⓘ

—

Debt / equityⓘ

—

ROAⓘ

—

ROEⓘ

—

Cash conversionⓘ

—

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

4,77

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-07 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	4,77
Revenue	—no estimate	—no estimate	20,4B TWD
Operating income	—no estimate	—no estimate	807,9M TWD

Full-year consensus mean (period as reported by source) · consensus in TWD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution4 analysts

Strong buy0

Buy0

Hold3

Sell0

Strong sell1

12-month price target$90,00 · Median $90,00

Low $85,00High $95,00

Operating income · consensus807,9M TWD

EPS surprise

−18,4 %

reported vs consensus · miss

Revenue surprise

−7,4 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$85,00

Mean$90,00

Median$90,00

High$95,00

Spot$70,10

+28.4 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskUnknown

Benchmarks vs cohort

No cohort benchmark data available for this issuer yet.

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted

Source documents

6469.TWO Market data — financials · 2026-05-27
Great Tree Pharmacy Co Ltd Market data — analyst estimates · 2026-05-27

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

6469.TWOCanonical

TPEx · TWD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskUnknown

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread